You just read:

Oncolytics Biotech® Inc.'s REOLYSIN® More than Doubles Overall Survival in Patients with Mutated p53 Metastatic Breast Cancer

News provided by

Oncolytics Biotech Inc.

Apr 05, 2017, 07:00 ET